Outcome measures
death, Prostate
RETROGRADE EJACULATION, RECURRENCE, ANEJACULATION, EVENT, PROSTATE, DISEASES
The patients’ urinary function was evaluated by RUV (mL, by ultrasonography), maximum flow rate (MFR, mL/s, by urodynamics), and International Prostate Symptom Score (IPSS). Erectile function and ejaculation function were evaluated by IIEF-5 and ejaculation function grading (Grade I: normal ejaculation; Grade II: retrograde ejaculation; Grade III: anejaculation), respectively. The initial results of postoperative urogenital function have been published in the previous paperThe oncological data included the 3-year overall survival (OS) and disease-free survival (DFS), and recurrence rate. Postoperative follow-up was performed every 3 months within 2 years, and every 6 months 3–5 years postoperatively. Comprehensive hematology, chest and abdomen spiral CT, and colonoscopy were used to evaluate the patient’s postoperative survival status. OS was calculated from the day of randomization until the day of death (event) or the day of the last follow-up examination (censored), while DFS was calculated from the day of randomization until the day of recurrence or death (event) or the day of the last follow-up examination (censored). Data were censored for patients with no evidence of diseases at the last follow-up examination or for patients who died from other diseases or reasons without evidence of recurrence. The last follow-up was on October 24, 2022.